全文获取类型
收费全文 | 192篇 |
免费 | 10篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 11篇 |
妇产科学 | 11篇 |
基础医学 | 31篇 |
口腔科学 | 3篇 |
临床医学 | 26篇 |
内科学 | 28篇 |
皮肤病学 | 2篇 |
神经病学 | 20篇 |
特种医学 | 5篇 |
外科学 | 12篇 |
综合类 | 1篇 |
预防医学 | 10篇 |
眼科学 | 1篇 |
药学 | 12篇 |
肿瘤学 | 25篇 |
出版年
2023年 | 4篇 |
2022年 | 1篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 4篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2015年 | 3篇 |
2014年 | 2篇 |
2013年 | 6篇 |
2012年 | 20篇 |
2011年 | 20篇 |
2010年 | 11篇 |
2009年 | 3篇 |
2008年 | 17篇 |
2007年 | 12篇 |
2006年 | 18篇 |
2005年 | 15篇 |
2004年 | 19篇 |
2003年 | 15篇 |
2002年 | 9篇 |
2000年 | 1篇 |
1998年 | 1篇 |
1996年 | 2篇 |
1986年 | 2篇 |
排序方式: 共有204条查询结果,搜索用时 62 毫秒
201.
Hervé Rubie Birgit Geoerger Didier Frappaz Antonin Schmitt Pierre Leblond Anna Ndiaye Isabelle Aerts Marie-Cécile Le Deley Jean-Claude Gentet Angelo Paci Pascal Chastagner Nathalie Dias Latifa Djafari Marlène Pasquet Etienne Chatelut Judith Landman-Parker Nadège Corradini Gilles Vassal 《European journal of cancer (Oxford, England : 1990)》2010,46(15):2763-2770
PurposeTo evaluate maximum tolerated dose and recommended dose (RD) for phase II studies of topotecan (TPT) combined with temozolomide (TMZ) (TOTEM) in children and adolescents with relapsed or refractory solid malignancies.Patients and methodsMulticentre, phase I study with a standard ‘3 + 3’ design in five dose increments. Eligible patients: aged 6 months to 21 years, diagnosis of a solid malignancy failed at least 2 previous lines of therapy. TMZ was administered orally, starting at 100 mg/m2/d, and TPT intravenously over 30 min, starting at 0.75 mg/m2/d over 5 consecutive days every 28 d. A pharmacokinetics analysis was performed on Day 1 and Day 5 of cycle 1.ResultsBetween February and October 2007, 16 patients were treated. The median age was 8.5 years (range, 3–19 years). Dose-limiting toxicity (grade 4 neutropenia and/or thrombocytopenia lasting more than 7 d) during the first cycle occurred in 2 of 3 patients at level 3 (TMZ 150 mg/m2/d and TPT 1.0 mg/m2/d) and was always manageable. Confirmed complete and partial responses were observed in 4 patients (25%), three with metastatic neuroblastoma and one with high-grade glioma. Seven patients had a stable disease. Pharmacokinetic data show a wide inter-individual variability. No significant differences were observed between plasma TMZ and TPT concentrations on Day 1 and Day 5 indicating the absence of pharmacokinetic interaction between the drugs.ConclusionsThe RD for the combination is TMZ 150 mg/m2/d and TPT 0.75 mg/m2/d with dose-limiting haematological toxicity. The observed activity deserves further evaluation in paediatric malignancies. 相似文献
202.
Pierre Fournel Gilles Robinet Pascal Thomas Pierre-Jean Souquet Hervé Léna Alain Vergnenégre Jean-Yves Delhoume Jacques Le Treut Jules-Antoine Silvani Eric Dansin Marie-Cécile Bozonnat Jean-Pierre Daurés Fran?oise Mornex Maurice Pérol 《Journal of clinical oncology》2005,23(25):5910-5917
PURPOSE: We conducted a phase III study to compare the survival impact of concurrent versus sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage III non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Patients were randomly assigned to one of the two treatment arms. In the sequential arm, patients received induction CT with cisplatin (120 mg/m2) on days 1, 29, and 57, and vinorelbine (30 mg/m2/wk) from day 1 to day 78, followed by thoracic RT at a dose of 66 Gy in 33 fractions (2 Gy per fraction and 5 fractions per week). In the concurrent arm, the same RT was started on day 1 with two concurrent cycles of cisplatin 20 mg/m2/d and etoposide 50 mg/m2/d (days 1 to 5 and days 29 to 33); patients then received consolidation therapy with cisplatin 80 mg/m2 on days 78 and 106 and vinorelbine 30 mg/m2/wk from days 78 to 127. RESULTS: Two hundred five patients were randomly assigned. Pretreatment characteristics were well balanced between the two arms. There were six toxic deaths in the sequential arm and 10 in the concurrent arm. Median survival was 14.5 months in the sequential arm and 16.3 months in the concurrent arm (log-rank test P = .24). Two-, 3-, and 4-year survival rates were better in the concurrent arm (39%, 25%, and 21%, respectively) than in the sequential arm (26%, 19%, and 14%, respectively). Esophageal toxicity was significantly more frequent in the concurrent arm than in the sequential arm (32% v 3%). CONCLUSION: Although not statistically significant, clinically important differences in the median, 2-, 3-, and 4-year survival rates were observed, with a trend in favor of concurrent chemoradiation therapy, suggesting that is the optimal strategy for patients with locally advanced NSCLC. 相似文献
203.
204.
Thomas Wirth MD PhD Guillemette Clément MD Clarisse Delvallée PhD Céline Bonnet MD PhD Thomas Bogdan MD Andra Iosif MD Audrey Schalk MD Jean-Baptiste Chanson MD PhD David Pellerin MD MSc Bernard Brais MDCM MPhil PhD Virginie Roth PhD Marion Wandzel PharmD Marie-Céline Fleury MD Amélie Piton PhD Nadège Calmels PharmD PhD Izzie Jacques Namer MD PhD Stéphane Kremer MD PhD Christine Tranchant MD PhD Mathilde Renaud MD PhD Mathieu Anheim MD PhD 《Movement disorders》2023,38(10):1950-1956